Pethidine Analgesia and Neonatal Hearing Screening Test

The study group consisted of patients receiving 50 mg intramuscular (I.M) pethidine at the beginning of the active phase of labor and the control group consisted of patients not receiving pethidine. Newborns were evaluated by otoacoustic emission (OAE) test. The OAE test was performed before the patients were discharged. Perinatal and neonatal variables and test results were recorded and the relationship between false positivity and pethidine use was evaluated.

Inclusion criteria

• term singleton pregnancy,
• Gave birth at 37-41 weeks of gestation,
• without chronic internal disease,
• Pregnant women were included in the study.

Exclusion criteria

• Newborn hospitalized in intensive care,
• congenital / chromosomal anomaly,
• congenital CMV infection,
• facial / ear deformities,
• family with hearing problems,
• those with hyperbilirunemia,
• tested at <12 hours after birth,
• maternal infection,
• Diabetes mellitus, recurrent abortion,
• smoking,
• plesanta previa,
• prolonged premature rupture of the membrane (more than 12 hours), epidural -analgesia and
• newborns who were at risk of asphyxia hypoxia were excluded from the study.